Event Title

Identification of the biomarker IL-23 in Glioblastoma multiforme cell line T98G using ELISA

Session Number

Project ID: MEDH 28

Advisor(s)

Dr. Sowmya Anjur, Illinois Mathematics and Science Academy

Discipline

Medical and Health Sciences

Start Date

20-4-2022 9:30 AM

End Date

20-4-2022 9:45 AM

Abstract

The prognosis for patients with Glioblastoma multiforme is about 6% within 5 years of diagnosis. However, if caught earlier, the astrocytes that form glioblastoma can be detected in order to treat and prevent the spread of the cancer. This makes the use of biomarkers useful for diagnosis and tracking the progression of Glioblastoma multiforme. ELISA tests were done to test Glioblastoma cell line T98G cell cultures for the IL-23 antigen, to identify its effectiveness as a biomarker. The concentration of IL-23 in the cells was read at 450 nm with a plate reader and quantified using known standards. Current testing indicates that the IL-23 biomarker will either be present in low amounts or be absent in the tissue samples studied.

Share

COinS
 
Apr 20th, 9:30 AM Apr 20th, 9:45 AM

Identification of the biomarker IL-23 in Glioblastoma multiforme cell line T98G using ELISA

The prognosis for patients with Glioblastoma multiforme is about 6% within 5 years of diagnosis. However, if caught earlier, the astrocytes that form glioblastoma can be detected in order to treat and prevent the spread of the cancer. This makes the use of biomarkers useful for diagnosis and tracking the progression of Glioblastoma multiforme. ELISA tests were done to test Glioblastoma cell line T98G cell cultures for the IL-23 antigen, to identify its effectiveness as a biomarker. The concentration of IL-23 in the cells was read at 450 nm with a plate reader and quantified using known standards. Current testing indicates that the IL-23 biomarker will either be present in low amounts or be absent in the tissue samples studied.